Patent ID: 11964057
Assignee: RJH BIOSCIENCES INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 19:
20. The method of claim 16, further comprising administering one or more drugs selected from Alemtuzumab, Arsenic Trioxide, Asparaginase, Azacitidine, Bendamustine Hydrochloride, Belinostat, Bleomycin, Blinatumomab, Bortezomib, Bosutinib, Brentuximab, Vedotin, Busulfan, Carmustine, Carfilzomib, Cladribine, Clofarabine, Chlorambucil, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dacarbazine, Daratumumab, Decitabine, Denileukin Diftitox, Doxorubicin Hydrochloride, Elotuzumab, Fludarabine Phosphate, Imatinib Mesylate, Hydroxyurea, Ibrutinib, Idarubicin Hydrochloride, Idelalisib, Intron A (Recombinant Interferon Alfa-2b), Ixazomib Citrate, Lenalidomide, Lomustine, Mercaptopurine, Mechlorethamine Hydrochloride, Methotrexate, Nelarabine, Nilotinib, Nivolumab, Obinutuzumab, Ofatumumab, Omacetaxine Mepesuccinate, Pamidronate Disodium, Panobinostat, Pegaspargase, Pembrolizumab, Plerixafor, Pomalidomide, Ponatinib Hydrochloride, Pralatrexate, Prednisone, Procarbazine Hydrochloride, Rituximab, Romidepsin, Thalidomide, Thioguanine, Tositumomab, Vincristine Sulfate, Venetoclax, Vinblastine Sulfate, Vorinostat, or Zoledronic Acid.